Catch up our lab representatives Jillian Egan and Christopher J. Magnani, MD MS presenting their work at #AUA24 !!

Christopher J. Magnani, MD MS May 5, 10:00AM, Texas Ballroom C: AUA-USAV podium presentation

Jillian Egan May 6, 7:00AM, Rm 301B: Bladder Cancer Basic Research & Pathophysiology III

👉📰Clinicopathological characteristics and eligibility for adjuvant #olaparib of germline BRCA1/2 mutation carriers with HER2-negative early #BreastCancer read it now in npj Journals Breast Cancer.
➡️pubmed.ncbi.nlm.nih.gov/38627457/
Stefania Morganti, MD Filipa Lynce, MD, FASCO G Curigliano MD PhD Nabihah Tayob

This recent study examined a subpopulation of luminal progenitors secretes pleiotrophin to promote angiogenesis and metastasis in #InflammatoryBreastCancer , read it here👇
Filipa Lynce, MD, FASCO #IBC
pubmed.ncbi.nlm.nih.gov/38507720/

Thank you for featuring our work! Yuzhen Zhou Vince D’Andrea, MD Raie Bekele Filipe LF Carvalho joaquim bellmunt Brigham and Women’s Radiation Oncology Dana-Farber Lank Center for Genitourinary Oncology

Catch up Jihyun Kate Lee computational biologist extraordinaire in the lab presenting her work on the implications of TME for cisplatin resistance in #bladdercancer #AACR24

Inflammatory breast cancer didn’t stop scuba diver Stephanie Lafontaine from pursuing her passions. Learn more about how Stephanie’s care team helped her reach remission + kept her exploring the ocean depths.

ms.spr.ly/6016c4e2M

#inflammatorybreastcancer #breastcancer

Our study on the prognosis of small TNBCs is out in npj Journals Breast. Among 8601 pts with stage I TNBC in SEER, we found excellent 5-year outcomes, with a significant BCSS benefit for chemo in pT1c. Benefit less clear in tumors ≤1cm: biomarkers needed! nature.com/articles/s4152…

The OXEL trial, led by Filipa Lynce, MD, FASCO, is out on Nature Communications. Among 45 pts with residual TNBC after NAT, adjuvant nivo/cape were well tolerated, increased peripheral immune score & led to numerically improved 2y iDFS (91%) vs nivo (47%) or cape alone (53%). nature.com/articles/s4146…

👇Our review on PARPi in breast cancer JAMA Oncology

⬆️ population who may benefit from PARPi
👀 new 💊 (PARP1-selective) to ⬇️ tox
🔥 novel combos w IO&ADCs

Amazing collaboration with 🇮🇹 🇺🇸 friends Stefania Morganti, MD Carmen Criscitiello Filipa Lynce, MD, FASCO G Curigliano MD PhD Giampaolo Bianchini IEO

Grateful to receive the National Cancer Institute Early-Stage Surgeon Scientist Program award. Thank you to mentors Eli Van Allen Kent Mouw and Dr. E Mittendorf for supporting me along the way. Exciting times ahead!

Addressing Residual Disease in #HER2 + and #TripleNegativeBreastCancer : What Is Next?
New #TNBC review in Current Oncology Reports from
Ilana Schlam #JoshuaDower Filipa Lynce, MD, FASCO
👉pubmed.ncbi.nlm.nih.gov/38393609/

One of my key research efforts is to expand the benefit of ADCs to pts with rare BC forms. On #RareDiseaseDay , I’d like to highlight 2 trials I had the chance to develop w/ Filipa Lynce, MD, FASCO & Dr Sarah Sammons:
-TRUDI➡️T-DXd/Durva for IBC
-DATO-Base➡️Dato-DXd for BCBM + LMD
Both enrolling!

Our #InflammatoryBreastCancer program led by Dr. Lynce (Filipa Lynce, MD, FASCO) is dedicated to providing comprehensive treatment and novel research. In addition to launching clinical trials and a patient registry we have established an #IBC Awareness Day (2nd Tues of Oct). #RareDiseaseDay

Let's celebrate #RareDiseaseDay by racing toward a cure for Inflammatory Breast Cancer. Join Team IBC The Jimmy Fund to raise much needed funds for IBC research and patient care! danafarber.jimmyfund.org/goto/TeamIBC20…
Antonio Giordano, MD PhD Paolo Tarantino Laura Warren, MD Dana-Farber’s Breast Oncology Center Meredith Regan, ScD Filipa Lynce, MD, FASCO

A great visit to AstraZeneca with Geoffrey Shapiro MD PhD and Filipa Lynce, MD, FASCO a few weeks ago to talk about targeting #macrophages in breast cancer. Excited about new clinical trials!

Who knows this chemical structure? Hint: It is our favorite class of drugs to study in the lab!

Dr. Glenn Hanna giving state-of-the-center for our early drug development program @danafarber_ccti 6-month tremendous growth - saying yes and saying no - to give patients more trial opportunities and treatment options. #phase1trial #CancerResearch Glenn J. Hanna, M.D.

For #trialtuesday , #CCTI_DFCI presents new trial 23-600 led by Filipa Lynce, MD, FASCO. IDE161, a PARG inhibitor, targets HRD and BRCA mutations in ER+ breast, endometrial, colorectal, and head and neck with these mutations. Different from PARPi. Dana-Farber
Visit: forms.office.com/r/kM7e6JVxre

'From serendipity to intention: development of brain penetrant PARP1 selective inhibitors' - recent commentary from Dr. Filipa Lynce (Filipa Lynce, MD, FASCO) and Dr. Nancy Lin (@nlinmd).
pubmed.ncbi.nlm.nih.gov/38251977/

Dana-Farber IBC Program Dana-Farber’s Breast Oncology Center Dana-Farber News Kornelia Polyak Filipa Lynce, MD, FASCO Dr. E Mittendorf Sara Tolaney Vaciry Eric Winer, MD Tari King MD Jane Brock BalkoResearchLab

We are thrilled to see our IBC clinical trial study is officially out in BreastCancerResearch. We found the use JAK1/2 inhibitor Ruxolitinib in TN-IBC resulted in decreased pSTAT3 but lack of clinical benefits. Comb with immunotherapy may need to be considered.
…ast-cancer-research.biomedcentral.com/articles/10.11…